– USA, CA – Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company, announced the appointment of Matthew Abernethy to its Board of Directors effective as of May 29, 2025, bringing over 15 years’ experience in corporate finance and investor relations in the biotech and medical device industry.
Additionally, the Company announced that Tim Coughlin stepped down from the Board of Directors.
“Mr. Abernethy is a highly accomplished financial and business leader in the biopharmaceutical industry, and we are delighted to welcome him to our Board of Directors,” said CEO, Dr. Bob Valamehr.
About Matthew Abernethy
Matt Abernethy is a leading financial executive with extensive experience in biopharma and medical devices. Since November 2017, he has served as CFO of Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, overseeing finance, accounting, information technology, and a variety of other functions. Before Neurocrine Biosciences, Inc., he held a variety of finance roles at Zimmer Biomet Holdings, Inc., a global medical technology leader, from February 2009 to November 2017.
Matt Abernethy began his career with KPMG LLP and became a certified public accountant (currently inactive).
“I feel privileged to be joining the Board of Directors of Fate Therapeutics at this transformative time when cell therapy has the potential to help many patients across both cancer and immunological disorders,” said Matt Abernethy.
Matt Abernethy holds a B.S. in Accounting and Business Administration from Grace College and an M.B.A. from the University of Chicago.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA.
For more: https://fatetherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.